Erik Skaaheim Haug
Overview
Explore the profile of Erik Skaaheim Haug including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Peters M, Eldred-Evans D, Kurver P, Falagario U, Connor M, Shah T, et al.
Eur Urol
. 2022 Aug;
82(5):559-568.
PMID: 35963650
Background: Although multiparametric magnetic resonance imaging (MRI) has high sensitivity, its lower specificity leads to a high prevalence of false-positive lesions requiring biopsy. Objective: To develop and externally validate a...
12.
Christiansen O, Bratt O, Kirkevold O, Saltyte Benth J, Manoharan P, Selnes A, et al.
Cent European J Urol
. 2022 May;
75(1):35-40.
PMID: 35591966
Introduction: Prostate-specific antigen (PSA) density has previously been identified as a predictor of histological upgrading at radical prostatectomy, but how information from pre-treatment biparametric magnetic resonance imaging (bpMRI) contributes needs...
13.
Cyll K, Loffeler S, Carlsen B, Skogstad K, Plathan M, Landquist M, et al.
Sci Rep
. 2022 Apr;
12(1):6743.
PMID: 35468921
Active surveillance (AS) is standard of care for patients with low-risk prostate cancer (PCa), but its feasibility in intermediate-risk patients is controversial. We compared outcomes of low- and intermediate-risk patients...
14.
15.
Nilssen Y, Brustugun O, Eriksen M, Guren M, Haug E, Naume B, et al.
BMC Cancer
. 2022 Mar;
22(1):220.
PMID: 35227226
Background: Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed...
16.
Carlsen B, Audun Klingen T, Andreassen B, Haug E
Diagn Pathol
. 2021 Nov;
16(1):109.
PMID: 34809660
Background: Lymphovascular invasion (VI) is an established prognostic marker for many cancers including bladder cancer. There is a paucity of data regarding whether the prognostic significance of lymphatic invasion (LVI)...
17.
Cyll K, Kleppe A, Kalsnes J, Vlatkovic L, Pradhan M, Kildal W, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503100
Machine learning (ML) is expected to improve biomarker assessment. Using convolution neural networks, we developed a fully-automated method for assessing PTEN protein status in immunohistochemically-stained slides using a radical prostatectomy...
18.
Nilsson R, Naess-Andresen T, Myklebust T, Bernklev T, Kersten H, Haug E
Eur Urol Open Sci
. 2021 Aug;
25:44-51.
PMID: 34337502
Background: Fear of recurrence (FoR) is a distressing consequence of cancer. Little is known about the prevalence of FoR in different treatment groups and factors associated with FoR among prostate...
19.
Korner S, Dreyer T, Haug E, Jerlstrom T, Bostrom P, Gudjonsson S, et al.
Scand J Urol
. 2021 Jan;
55(2):135-141.
PMID: 33504267
Objective: The aim of this study was to give a collective overview on all available data sources on bladder cancer patients in the Nordic countries including the amount of detail...
20.
Nilssen Y, Brustugun O, Eriksen M, Haug E, Naume B, Moller B
BMC Cancer
. 2020 Jun;
20(1):488.
PMID: 32473650
Background: Cancer patient pathways (CPPs) were implemented in 2015 to reduce waiting time, regional variation in waiting time, and to increase the predictability of cancer care for the patients. The...